WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies closed a registered direct offering and concurrent private placement, generating approximately $4 million in gross proceeds before fees and expenses. It sold common stock or pre-funded warrants at $6.122 per share (or $6.115 per pre-funded warrant) and issued warrants to purchase up to 980,072 shares at $6.122 each, subject to stockholder approval. The company expects to use net proceeds for working capital, support anticipated growth in CyPath Lung sales, and general corporate purposes.

Analysis

The financing buys BIAF time, but does not establish that CyPath® Lung demand is scaling: the stated sales-growth rationale is management intent, not independently verified traction. The key underwriting question is whether net proceeds extend runway long enough to demonstrate repeatable test volume, reimbursement, and collection economics. The common/pre-funded securities create near-term dilution; the additional 980,072-share warrant package is a contingent overhang, dependent on stockholder approval and future trading above its $6.122 strike. Warrant proceeds should not be counted as available liquidity today.

Near term, the financing may reduce acute funding risk, while the issue price and warrant strike can become reference points for trading; neither is a guaranteed floor. Over 1–3 months, stockholder approval and subsequent commercial disclosures matter more than the financing headline. Over 6–18 months, evidence of adoption and cash conversion—or another capital raise—will determine whether this was bridge financing or merely deferred dilution. The contrarian angle is that the raise is not automatically bearish if it enables measurable commercial proof; conversely, the phrase “expected growing sales” risks being mistaken for demonstrated momentum. No sector read-through is warranted from a small, company-specific raise.

Key Decisions for Investors

• Do not treat the warrant proceeds as committed capital. Verify net proceeds, the pro forma fully diluted share count, current cash, quarterly burn, and stockholder-approval status in SEC filings before sizing exposure.
• For an event-driven book, remain neutral to underweight BIAF until disclosed test volumes, reimbursement/collection data, and cash runway substantiate the commercial narrative; avoid initiating a directional short without borrow, liquidity, and valuation checks.
• Use $6.122 as a financing/strike reference, not a price target or support level. A sustained move below it alongside weak commercial disclosures would reinforce dilution and financing-risk concerns; a sustained move above it alone does not prove demand.
• Reassess if the next filings show improving paid test volumes and runway without another near-term raise; that would weaken the dilution thesis. A further financing, missed sales expectations, or limited runway would strengthen it.